C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC)

CUSIP: 12529R107

Q3 2025 13F Holders as of 30 Sep 2025

Holder snapshot 7 signals
Share change
-2,025,201
Put/Call ratio
56%
SEC-reported price per share
$2.22
Indexed holders
96
Value change
-$3,450,925
Number of buys
47
Open additional details 1 more signal available
Number of sells
62
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
137,921,939

Security key

12529R107

Report period

Q3 2025

Indexed institutions

96

Top holders

10

Ownership snapshot

Top reported holders of CCCC - C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
WASATCH ADVISORS LP
Disclosed value leader
Alain J. Cohen
Comparable rows
1/15
Latest evidence
30 Sep 2025
13D/G 13F 3/4/5 Lead comparable stake: 6.8% 14 rows are not safely comparable across share classes. 13D/G row: WASATCH ADVISORS LP Showing 1-6 of 15 holder rows.

Quick read

WASATCH ADVISORS LP leads the comparable SEC ownership view at 6.8%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens WASATCH ADVISORS LP's linked filing trail.
Comparable ownership Top 1
WASATCH ADVISORS LP 6.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
WASATCH ADVISORS LP
13D/G 13F
Company
6.8%
Reported 13D/G · 30 Sep 2025
$10,773,085
4,852,741 shares
-$5,817,712 30 Sep 2025
Alain J. Cohen
3/4/5
Director
—
denominator unverified
$11,770,243
1,805,252 shares
— 04 Apr 2022
Lynx1 Capital Management LP
13F
Company
13F
—
denominator unverified
$10,150,330
7,098,133 shares
— 30 Jun 2025
Soleus Capital Management, L.P.
13F
Company
13F
—
denominator unverified
$9,979,887
6,978,942 shares
— 30 Jun 2025
ORBIMED ADVISORS LLC
13F
Company
13F
—
denominator unverified
$9,767,329
6,830,300 shares
— 30 Jun 2025
MORGAN STANLEY
13F
Company
13F
—
denominator unverified
$6,798,489
4,754,188 shares
— 30 Jun 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
96
Shares
52,538,995
Indexed holders
96
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 indexed holders
102
Q3 2025 indexed holders
96
Indexed holder difference
-6
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 value Q3 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .